BodeiL, CremonesiM, FerrariMet al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors. Eur J Nucl Med Mol Imaging, 2008; 35:1847.
LassmannM, StrigariL, BardièsM. Dosimetry is alive and well. Cancer Biother Radiopharm, 2010; 25:593.
6.
WesselsBW, KonijnenbergMW, DaleRGet al. MIRD pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response—implications for radionuclide therapy. J Nucl Med, 2008; 49:1884.
7.
CremonesiM, BottaF, Di DiaAet al. Dosimetry for treatment with radiolabelled somatostatin analogues: A review. Q J Nucl Med Mol Imag, 2010; 54:37.
8.
BaroneR, Borson-ChazotF, ValkemaRet al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose–effect relationship. Nucl Med, 2005; 46,suppl1:99S.
9.
De JongM, ValkemaR, Van GamerenAet al. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. J Nucl Med, 2004; 45:1168.
10.
MelisM, KrenningEP, BernardBFet al. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imag, 2005; 32:1136.
11.
KonijnenbergM, MelisM, ValkemaRet al. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med, 2007; 48:134.
12.
BouchetLG, BolchWE, BlancoHPet al. MIRD Pamphlet No 19: Absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med, 2003; 44:1113.
13.
KwekkeboomDJ, KamBL, van EssenMet al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer, 2010; 17:R53.
